Depressive disorder in patients with epilepsy

Depressive disorder is one of the most common psychiatric comorbidities among individuals with epilepsy. Depression may occur before the onset of seizures, during the course of epilepsy, or as a consequence of recurrent seizures and psychosocial difficulties associated with the condition. Depression negatively affects treatment adherence, seizure control, quality of life, and overall prognosis.

Early recognition and appropriate management are essential because depressive symptoms are often underdiagnosed and undertreated in patients with epilepsy.

Epidemiology

Depression is significantly more common in individuals with epilepsy than in the general population. The prevalence is highest among patients with chronic epilepsy, refractory epilepsy, and those experiencing significant psychosocial impairment.

Risk Factors

• Poorly controlled epilepsy

• Frequent seizures

• Long duration of epilepsy

• Social isolation

• Unemployment

• Stigma related to epilepsy

• Cognitive impairment

• Family history of depression

• Certain antiepileptic medications

• Coexisting anxiety disorders

Pathophysiology

Several mechanisms contribute to depression in epilepsy:

• Shared neurobiological pathways involving limbic structures

• Altered serotonin and norepinephrine neurotransmission

• Structural abnormalities within temporal and frontal lobes

• Psychosocial stress associated with chronic illness

• Adverse effects of certain antiepileptic drugs

Clinical Presentation

Symptoms

• Persistent sadness

• Loss of interest or pleasure

• Fatigue

• Sleep disturbances

• Poor concentration

• Feelings of hopelessness

• Reduced appetite

• Social withdrawal

• Low self-esteem

• Suicidal thoughts

Clinical Signs

• Depressed mood

• Reduced emotional reactivity

• Psychomotor slowing

• Impaired concentration

• Poor motivation

• Neglected self-care

Diagnostic Criteria

Diagnosis is based on:

• Presence of depressive symptoms

• Functional impairment

• Established diagnosis of epilepsy

• Exclusion of medication-induced symptoms

• Exclusion of other psychiatric disorders

• Comprehensive psychiatric assessment

Investigations

Laboratory Investigations

• Full blood count

• Blood glucose

• Liver function tests

• Renal function tests

• Thyroid function tests where indicated

Neurological Assessment

• Review seizure frequency

• Review antiepileptic medications

• EEG and neuroimaging where clinically indicated

Psychiatric Assessment

• Mental status examination

• Depression severity assessment

• Suicide risk assessment

Management

The primary treatment goal is optimization of seizure control while addressing depressive symptoms.

Non-Pharmacological Treatment

• Psychoeducation to the patient and family

• Family therapy

• Supportive group therapy

• Occupational therapy

• Psychotherapy where available

• Lifestyle modification

• Social support interventions

Pharmacological Treatment

Optimize antiepileptic therapy using one of the following:

• Carbamazepine (PO) 200–1000 mg per day in divided doses. Symptoms should be monitored and medication titrated accordingly.

OR

• Phenobarbitone (PO) 30–200 mg per day in divided doses. Symptoms should be monitored and medication titrated accordingly.

OR

• Sodium valproate (PO) 500–2000 mg per day in divided doses. Symptoms should be monitored and medication titrated accordingly.

AND

Use one of the following antidepressants:

• Amitriptyline (PO) 12.5–75 mg at night. Symptoms should be monitored and medication titrated accordingly.

OR

• Fluoxetine (PO) 10–20 mg per day in divided doses. Symptoms should be monitored and medication titrated accordingly.

Management

according to underlying cause

Depression Related to Poor Seizure Control

• Prioritize optimization of seizure control

• Improve medication adherence

• Address psychosocial stressors

Depression Associated with Antiepileptic Medication

• Review current therapy

• Consider alternative antiepileptic treatment where appropriate

• Monitor closely for symptom improvement

Referral

Refer the patient when:

• Severe depression is present

• Suicidal ideation or behavior occurs

• Symptoms do not respond to treatment

• Diagnostic uncertainty exists

• Specialized psychiatric care is required

Complications

• Suicide and self-harm

• Poor seizure control

• Medication non-adherence

• Social dysfunction

• Occupational impairment

• Reduced quality of life

Prognosis

The prognosis is generally favorable when depression is identified early and treated appropriately. Improved seizure control is often associated with improved mood, psychosocial functioning, and quality of life.

Prevention

• Early diagnosis of epilepsy

• Effective seizure control

• Regular mental health screening

• Patient and family education

• Social support

• Prompt treatment of depressive symptoms

Special Considerations

• Priority should be given to optimizing seizure control because improved psychosocial functioning often accompanies seizure remission.

• Sodium valproate, gabapentin, carbamazepine, and lamotrigine may have antidepressant properties.

• Phenobarbital is known to produce depressive symptoms and should be considered when evaluating mood changes.